Critical Contrast: Ainos (OTCMKTS:AIMD) versus CVRx (NASDAQ:CVRX)

Ainos (OTCMKTS:AIMD) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Ainos and CVRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	N/A
CVRx	0	2	5	0	2.71

CVRx has a consensus price target of $13.67, suggesting a potential upside of 44.01%. Given CVRx’s higher possible upside, analysts clearly believe CVRx is more favorable than Ainos.

Valuation and Earnings

This table compares Ainos and CVRx”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$65,122.00	54.92	-$14.01 million	($2.55)	-0.22
CVRx	$44.39 million	4.62	-$41.20 million	($2.47)	-3.84

Ainos has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ainos and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-515.80%	-44.32%	-40.35%
CVRx	-122.52%	-77.62%	-51.34%

Risk & Volatility

Ainos has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, CVRx has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Institutional & Insider Ownership

0.3% of Ainos shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 4.6% of Ainos shares are owned by company insiders. Comparatively, 18.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

CVRx beats Ainos on 7 of the 13 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.